Top View
- WO 2010/017573 Al
- Developing and Regulating Engineered Therapeutic Proteins
- (CADA) Analogs to Target Signal Peptides
- (12) United States Patent (10) Patent No.: US 8,883,817 B2 Sadée Et Al
- Fourth Release
- (12) United States Patent (10) Patent No.: US 9.456,986 B2 Rey Et Al
- Mai Motomontant De La Toma Di Tutto
- Feasibility of Polymer-Drug Conjugates for Non-Cancer Applications
- (12) Patent Application Publication (10) Pub. No.: US 2009/011 1844 A1 Sadee Et Al
- Billing Code 4410-09-P DEPARTMENT of JUSTICE Drug Enforcement Administration [Docket No. DEA-372] Exempt Chemical Preparations U
- Dosage Form Containing Oxycodone and Naloxone Darreichungsform Enthaltend Oxycodon Und Naloxon Forme Posologique Contenant De L’Oxycodone Et De La Naloxone
- Clinical Pharmacology Biopharmaceutics Review(S)
- (12) United States Patent (10) Patent No.: US 8,183,376 B2 Cheng Et Al
- Sunday, October 18, 2015 • Registration Opens (8:00Am-6:00Pm)
- (12) United States Patent (10) Patent No.: US 8,273,888 B2 Grote Et Al
- NALOXEGOL Tablets (Moventig® )
- Program & Abstracts
- Opioid Receptor Inhibitors (Inhibitors, Agonists and Modulators)
- Analytical Reference Standards
- (12) United States Patent (10) Patent No.: US 8,168,790 B2 Bao Et Al
- Controlling Opioid Receptor Functional Selectivity by Targeting Distinct Subpockets of the Orthosteric Site
- Development of an LC/MS-MS Naloxone Hydrolysis Assay Using a Recombinant Beta-Glucuronidase for Urinalysis”
- Third Release
- Machine Learning Harnesses Molecular Dynamics to Discover New Μ Opioid Chemotypes